Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis.

Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis. J Hepatol. 2019 04; 70(4):735-744.

View in: PubMed

subject areas

Adult
Anticholesteremic Agents
Biomarkers
Biopsy
Cholestenones
Cholesterol, HDL
Cholesterol, LDL
Drug Therapy, Combination
Female
Fibroblast Growth Factors
Humans
Lipoproteins, VLDL
Liver
Male
Middle Aged
Non-alcoholic Fatty Liver Disease
Rosuvastatin Calcium
Treatment Outcome
Triglycerides

authors with profiles

Mary Rinella